Imugene
Sydney, New South Wales, Australia · Biotechnology, Health Care, Medical
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour res
Key facts
- Headquarters
- Sydney, New South Wales, Australia
- Employees
- 23
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- imugene.com
- Company page
Recent activity at Imugene
Leadership
- Leslie Chong, Chief Executive Officer
- Darren Keamy, Chief Financial Officer
- John Byon, Senior Vice President of Clinical Development
Verified email and direct lines for Imugene’s decision-makers are on Fundz. See plans
Imugene in the news
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU) - Yahoo Finance (May 20, 2026)
- Imugene reports strong early responses to Azer-cel in CAR-T naïve blood cancer patients - BiotechDispatch (May 26, 2026)
- Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL - PR Newswire (Jul 14, 2025)
- Imugene and Kincell Bio Announce Strategic Manufacturing and Process Development Partnership - GlobeNewswire (Apr 16, 2024)
- Imugene launches $20 million capital raise to fund expansion of Azer Cel trials - BiotechDispatch (Mar 12, 2026)
- Imugene’s Azer-Cel Shows Promise in Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Applied Clinical Trials (Jul 16, 2025)
- Imugene (ASX: IMU) up 155% this week - maybe this cancer-killing virus really works? - Dhaka Tribune (Nov 09, 2023)
- Imugene CMO and CEO talk trial momentum and immuno-oncology progress - YouTube (Jun 02, 2025)
Companies similar to Imugene
- OncoNano Medicine · Biotechnology, Health Care, Medical, Therapeutics
- NuCana · Biotechnology, Health Care, Medical, Therapeutics
- Aethlon Medical · Biotechnology, Health Care, Medical, Therapeutics
- NRx Pharmaceuticals · Biotechnology, Health Care, Medical, Therapeutics
- Aerska · Biotechnology, Health Care, Medical, Therapeutics
About Imugene: questions and answers
What does Imugene do?
Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. onCARlytics (CF33-CD19) is a novel and effective combination immunotherapy utilising the CF33 oncolytic virus to deliver and present CD19 antigen on the surface of cancer cells promoting CD19 CAR T cell anti-tumour res
Where is Imugene headquartered?
Imugene is headquartered in Sydney, New South Wales, Australia.
How many employees does Imugene have?
Imugene has about 23 employees.
Who leads Imugene?
Leslie Chong is a Chief Executive Officer at Imugene.
What is the latest news on Imugene?
On Jul 27, 2026, Imugene Limited Announces Resignation of CEO Leslie Chong Effective Immediately
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy